Literature DB >> 23960831

Hospital versus home treatment of deep vein thrombosis in a tertiary care hospital in Saudi Arabia: Are we ready?

Farjah Algahtani1, Zohair Al Aseri, Abdurahman Aldiab, Aamer Aleem.   

Abstract

AIM/
BACKGROUND: Treatment of DVT with LMWHs has been shown recently to be as effective as UFH with suggested lower costs. This study was conducted to determine and compare the cost of in-patient hospital treatment versus outpatient hospital treatment of patients with DVT.
METHOD: All adult patients with acute proximal DVT referred to the Emergency Department of King Khalid University Hospital, Riyadh, Saudi Arabia between August 2009 and August 2010 were invited to the study. An economic analysis was performed to compare the cost impact of outpatients versus hospital treatment.
RESULTS: Sixty-one patients were included in the study, 31 were followed in the outpatient setting and 30 as the control group (inpatients). There were no significant differences in the outcome between the outpatient and inpatient group; three patients (9.7%) in the outpatient group and four patients (13.3%) in the inpatient group had recurrent DVT. Mean nursing cost was $55 for the outpatient group and $215 for the inpatient group, mean laboratory monitoring cost was $638 for outpatient group and $1511 for the inpatient group. Hospital stay and doctor's fees amounted to a mean of $1000 for outpatient treatment and $2387 for inpatient treatment, p < 0.0001. The mean outpatient cost was significantly lower than the inpatient cost ($1750 vs. $4338, p < 0.0001).
CONCLUSION: Outpatient treatment of patients with DVT using LMWHs is cost-effective with no significant differences in the outcome of patients. OPD treatment of DVT is feasible in Saudi Arabia provided there is enough logistic support from thrombosis clinics and those involved in DVT care.

Entities:  

Keywords:  Anticoagulation; Deep vein thrombosis; Economic evaluation; Outpatient; Patient safety; Treatment

Year:  2012        PMID: 23960831      PMCID: PMC3745076          DOI: 10.1016/j.jsps.2012.05.008

Source DB:  PubMed          Journal:  Saudi Pharm J        ISSN: 1319-0164            Impact factor:   4.330


  23 in total

1.  Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group.

Authors:  P Lindmarker; M Holmström
Journal:  J Intern Med       Date:  1996-12       Impact factor: 8.989

2.  Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.

Authors:  M K Gould; A D Dembitzer; G D Sanders; A M Garber
Journal:  Ann Intern Med       Date:  1999-05-18       Impact factor: 25.391

3.  Heparin kinetics in venous thrombosis and pulmonary embolism.

Authors:  J Hirsh; W G van Aken; A S Gallus; C T Dollery; J F Cade; W L Yung
Journal:  Circulation       Date:  1976-04       Impact factor: 29.690

4.  Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.

Authors:  H R Büller; M Gent; A S Gallus; J Ginsberg; M H Prins; R Baildon
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

5.  Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.

Authors:  R D Hull; G E Raskob; R F Brant; G F Pineo; K A Valentine
Journal:  Arch Intern Med       Date:  1997 Dec 8-22

6.  Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

Authors:  G Merli; T E Spiro; C G Olsson; U Abildgaard; B L Davidson; A Eldor; D Elias; A Grigg; D Musset; G M Rodgers; A A Trowbridge; R D Yusen; K Zawilska
Journal:  Ann Intern Med       Date:  2001-02-06       Impact factor: 25.391

7.  Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis.

Authors:  A Leizorovicz; G Simonneau; H Decousus; J P Boissel
Journal:  BMJ       Date:  1994-07-30

8.  Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis.

Authors:  S Siragusa; B Cosmi; F Piovella; J Hirsh; J S Ginsberg
Journal:  Am J Med       Date:  1996-03       Impact factor: 4.965

9.  A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis.

Authors:  Samuel Z Goldhaber; Victor F Tapson
Journal:  Am J Cardiol       Date:  2004-01-15       Impact factor: 2.778

10.  Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.

Authors:  P Lindmarker; M Holmström; S Granqvist; H Johnsson; D Lockner
Journal:  Thromb Haemost       Date:  1994-08       Impact factor: 5.249

View more
  5 in total

Review 1.  Carers' Medication Administration Errors in the Domiciliary Setting: A Systematic Review.

Authors:  Anam Parand; Sara Garfield; Charles Vincent; Bryony Dean Franklin
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

2.  Recurrent Deep Vein Thrombosis After the First Venous Thromboembolism Event: A Single-Institution Experience.

Authors:  Mohammad Asim; Hassan Al-Thani; Ayman El-Menyar
Journal:  Med Sci Monit       Date:  2017-05-20

Review 3.  Costs associated with management of non-communicable diseases in the Arab Region: a scoping review.

Authors:  Shadi Saleh; Amena El Harakeh; Maysa Baroud; Najah Zeineddine; Angie Farah; Abla Mehio Sibai
Journal:  J Glob Health       Date:  2018-12       Impact factor: 4.413

4.  The Saudi Clinical Practice Guideline for the treatment of venous thromboembolism. Outpatient versus inpatient management.

Authors:  Fahad M Al-Hameed; Hasan M Al-Dorzi; Abdulkarim M Al-Momen; Farjah H Algahtani; Hazzaa A Al-Zahrani; Khalid A Al-Saleh; Mohammed A Al-Sheef; Tarek M Owaidah; Waleed Alhazzani; Ignacio Neumann; Wojtek Wiercioch; Jan Brozek; Holger Schunemann; Elie A Akl
Journal:  Saudi Med J       Date:  2015-08       Impact factor: 1.484

5.  Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline.

Authors:  Fahad Al-Hameed; Hasan M Al-Dorzi; Abdulkarim AlMomen; Farjah Algahtani; Hazzaa AlZahrani; Khalid AlSaleh; Mohammed AlSheef; Tarek Owaidah; Waleed Alhazzani; Ignacio Neumann; Wojtek Wiercioch; Jan Brozek; Holger Schünemann; Elie A Akl
Journal:  Ann Saudi Med       Date:  2015 Mar-Apr       Impact factor: 1.526

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.